Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 320

1.

Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models.

Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX, Cheung NK, Ross GD.

J Immunol. 2004 Jul 15;173(2):797-806.

2.

Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.

Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, Ostroff GR, Ross GD.

Cancer Res. 2003 Dec 15;63(24):9023-31.

3.
5.

Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies.

Cheung NK, Modak S, Vickers A, Knuckles B.

Cancer Immunol Immunother. 2002 Nov;51(10):557-64. Epub 2002 Sep 20.

PMID:
12384807
6.

Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan.

Yan J, Vetvicka V, Xia Y, Hanikýrová M, Mayadas TN, Ross GD.

Immunopharmacology. 2000 Jan;46(1):39-54.

PMID:
10665778
7.

Effects of beta-glucans on the immune system.

Akramiene D, Kondrotas A, Didziapetriene J, Kevelaitis E.

Medicina (Kaunas). 2007;43(8):597-606. Review.

8.

Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer.

Yan J, Allendorf DJ, Brandley B.

Expert Opin Biol Ther. 2005 May;5(5):691-702. Review.

PMID:
15934844
9.

C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan.

Allendorf DJ, Yan J, Ross GD, Hansen RD, Baran JT, Subbarao K, Wang L, Haribabu B.

J Immunol. 2005 Jun 1;174(11):7050-6.

10.

Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18).

Thornton BP, Vĕtvicka V, Pitman M, Goldman RC, Ross GD.

J Immunol. 1996 Feb 1;156(3):1235-46.

PMID:
8558003
11.

Therapeutic intervention with complement and beta-glucan in cancer.

Ross GD, Vetvicka V, Yan J, Xia Y, Vetvicková J.

Immunopharmacology. 1999 May;42(1-3):61-74. Review.

PMID:
10408367
12.

Activation of rat macrophages by Betafectin PGG-glucan requires cross-linking of membrane receptors distinct from complement receptor three (CR3).

Michalek M, Melican D, Brunke-Reese D, Langevin M, Lemerise K, Galbraith W, Patchen M, Mackin W.

J Leukoc Biol. 1998 Sep;64(3):337-44.

PMID:
9738660
13.
14.

The function of human NK cells is enhanced by beta-glucan, a ligand of CR3 (CD11b/CD18).

Di Renzo L, Yefenof E, Klein E.

Eur J Immunol. 1991 Jul;21(7):1755-8.

PMID:
2060581
16.

Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway.

Li B, Allendorf DJ, Hansen R, Marroquin J, Ding C, Cramer DE, Yan J.

J Immunol. 2006 Aug 1;177(3):1661-9.

17.

Treatment of Lewis lung carcinoma by photodynamic therapy and glucan from barley.

Akramiene D, Grazeliene G, Didziapetriene J, Kevelaitis E.

Medicina (Kaunas). 2009;45(6):480-5.

19.

Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan.

Modak S, Koehne G, Vickers A, O'Reilly RJ, Cheung NK.

Leuk Res. 2005 Jun;29(6):679-83.

PMID:
15863209
20.

Therapeutic potential of various beta-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy.

Driscoll M, Hansen R, Ding C, Cramer DE, Yan J.

Cancer Biol Ther. 2009 Feb;8(3):218-25. Epub 2009 Feb 3.

PMID:
19106638

Supplemental Content

Support Center